Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Capecitabine in Head and Neck Cancer
NCT00258310Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Dec 2003
- Primary completion
- Feb 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Compliance With Treatment at 365 days. Started Dec 2003; status: completed.
02
Drugs
capecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00258310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258310.